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YKL-40 is a chitinase-like glycoprotein produced by alternatively activated macrophages that are associated with wound healing
and ﬁbrosis. Asbestosis is a chronic asbestos-induced lung disease, in which injury of epithelial cells and activation of alveolar
macrophages lead to enhanced collagen production and ﬁbrosis. We studied if YKL-40 is related to inﬂammation, ﬁbrosis, and/or
lung function in subjects exposed to asbestosis. Venous blood samples were collected from 85 men with moderate or heavy
occupational asbestos exposure and from 28 healthy, age-matched controls. Levels of plasma YKL-40, CRP, IL-6, adipsin, and
MMP-9 were measured with enzyme-linked immunosorbent assay (ELISA). Plasma YKL-40 levels were signiﬁcantly higher in
subjects with asbestosis (n = 19) than in those with no ﬁbrotic ﬁndings in HRCT following asbestos exposure (n = 66) or in
unexposed healthy controls. In asbestos-exposed subjects, plasma YKL-40 correlated negatively with lung function capacity
parameters FVC (Pearson’s r −0.259, p = 0 018) and FEV1 (Pearson’s r −0.240, p = 0 028) and positively with CRP (Spearman’s
rho 0.371, p < 0 001), IL-6 (Spearman’s rho 0.314, p = 0 003), adipsin (Spearman’s rho 0.459, p < 0 001), and MMP-9 (Spearman’s
rho 0.243, p = 0 025). The present ﬁnding suggests YKL-40 as a biomarker associated with ﬁbrosis and inﬂammation in asbestos-
exposed subjects.
1. Introduction
Asbestosis is a chronic interstitial ﬁbrosing lung disease
developing slowly after exposure to asbestos ﬁbers. As the
clearance of these ﬁbers is very slow, exposure to asbestos
can lead to chronic inﬂammatory changes and eventually to
clinically detectable ﬁbrosis after a latent period. In the
pathogenesis of asbestosis, ﬁbrosis is located ﬁrst at the site
of asbestos bodies, where macrophages accumulate and
inﬂammatory reaction takes place, followed by a more
diﬀuse ﬁbrosis in the lungs, which is characterized by
apoptosis of epithelial cells, ﬁbroblast proliferation, and
collagen deposition [1].
Asbestosis is classiﬁed as a rare disease by Orphanet
portal for rare diseases [2] (i.e., it is aﬀecting less than one
person per 2000 in the European population, as deﬁned
by the EU Commission Public Health Policy on Rare
Diseases [3]). In western countries, the use of asbestos
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has been banned or restricted in the developed countries
starting from 1990s: asbestos is not anymore used in con-
struction work today, and the risks of asbestos ﬁbers in
renovation are acknowledged [4, 5]. As ﬁbrosis manifests
15 to 40 years after exposure to asbestos and highest level
of asbestos use took place in the 1970s and 1980s in Euro-
pean countries, peak in the incidence of asbestos-related
diseases is now levelling oﬀ [1, 4]. In contrast, asbestos
use is still signiﬁcant or increasing in countries such as
Brazil, China, India, Iran, Kazakhstan, Russia, Thailand,
and Ukraine [4]. The World Health Organization
(WHO) has estimated that about 125 million people are
still exposed to asbestos at the workplace and half of the
deaths from occupational cancer are caused by asbestos
[5, 6]. Measures to prevent exposure to asbestos are the
most eﬃcient way to eliminate these diseases, but the
WHO calls also for improvements in diagnostics and
treatment. Investigation of inﬂammatory and ﬁbrotic pro-
cesses in asbestosis is needed to allow drug development
and to ﬁnd novel biomarkers to diagnose and follow up
these diseases [6].
YKL-40, a chitin-binding glycoprotein without the cata-
lytic activity characteristic to the true chitinases, is related
to various inﬂammatory and tissue-remodeling diseases.
YKL-40 and its homologues are known by various names
such as chitinase-3-like protein 1 (Chi3-l1), breast regression
protein 39 (BRP-39), human cartilage glycoprotein 39 (HC
gp-39), and chondrex [7, 8]. YKL-40 has been shown to asso-
ciate with ﬁbrosis and macrophage activation [8–10].
Increased circulating levels of YKL-40 were reported in
ﬁbrotic liver disease: high YKL-40 levels are associated with
histologically more severe ﬁbrotic changes in chronic alco-
holic hepatitis, primary biliary cirrhosis, autoimmune
hepatitis-induced cirrhosis, and hepatitis C [11–14], and
YKL-40 was described as a marker of treatment response in
interferon-treated patients with hepatitis C [14]. High YKL-
40 levels have also been shown to associate with various
forms of interstitial lung diseases (ILD), such as idiopathic
pulmonary ﬁbrosis (IPF), idiopathic nonspeciﬁc interstitial
pneumonia (iNSIP), and cryptogenic organizing pneumoni-
tis (COP) [15–17]. The aim of the present study was to inves-
tigate the hypothesis that YKL-40 is related to inﬂammation,
ﬁbrosis, and/or lung function in asbestos-exposed subjects.
2. Materials and Methods
2.1. Subjects. The study subjects (one hundred and eighteen
men) were recruited among individuals with known history
of moderate or heavy occupational exposure to asbestos
who were therefore followed up at the Clinic of Occupational
Medicine at Tampere University Hospital [18]. All of them
were nonsmokers or had quit over ﬁve years previously.
Thirty-three men were excluded due to meeting the exclu-
sion criteria that were asthma or asthma medication,
FEV1/FVC < 0.7, and bronchiectasis or emphysema on
high-resolution computed tomography (HRCT) of the
chest. The remaining 85 men formed the asbestos-
exposed group in the study, and they were further divided
into two groups according to the HRCT ﬁndings: 66 had
normal lung parenchyma (HRCT class 0) or only minor
borderline ﬁbrotic ﬁndings (HRCT class 1), and 19 had
bilateral parenchymal ﬁbrosis, that is, asbestosis (HRCT
classes 2–5), see below. The control group was recruited
from the community and consisted of 28 healthy non-
smoking men with no respiratory symptoms and normal
lung function. This study was approved by the Ethics
Committee of Tampere University Hospital. All the
subjects gave their written informed consent.
2.2. HRCT. HRCT was scanned (Siemens Somatom Plus 4;
Siemens Medical, Erlangen, Germany) with 1mm slices
taken at 3 cm intervals using imaging parameters of 130–
140 kV and 100–111mA. The HRCT images were scored
using consensus reading by two experienced thoracic radiol-
ogists as described previously [19, 20]. Findings indicating
interstitial lung ﬁbrosis (septal thickening, subpleural lines,
parenchymal bands, or honeycombing) in both lungs were
semiquantitatively scored according to a scale of classes from
0 to 5. Class 0 represents normal parenchymal ﬁnding, class 1
represents borderline parenchymal ﬁnding with minor
sporadic changes only, and classes 2 to 5 represent mild to
extreme diﬀuse pulmonary ﬁbrosis [19].
2.3. Measurements of Circulating Biomarkers. Venous blood
samples were drawn, and plasma/serum samples were stored
at −70°C until analyzed. Enzyme-linked immunosorbent
assay (ELISA) was performed using commercial reagents
for YKL-40, adipsin, MMP-9, CRP (R&D Systems Europe
Ltd., Abingdon, U.K.), and IL-6 (Sanquin, Amsterdam, The
Netherlands).
2.4. Statistical Analysis. Distribution of plasma YKL-40 was
skewed (Kolmogorov-Smirnov’s test), and log transforma-
tion was used in statistical calculations to guarantee normally
distributed data when needed. Correlations were calculated
using Pearson’s r between normally distributed variables
and Log-YKL-40 and by using Spearman’s rho between
nonnormally distributed variables and YKL-40. Normally
distributed data are presented as mean (SD) and skewed data
as median (interquartile range, IQR). Comparison between
groups was performed with unpaired t-test, Mann–Whitney
U test, or one-way ANOVA with least signiﬁcant diﬀerence
(LSD) posttest where appropriate. p values less than 0.05
were considered signiﬁcant. SPSS Statistics 23 software (SPSS
Inc., Chicago, IL, USA) was used in the statistical analysis.
3. Results
Subject characteristics, lung function parameters, and circu-
lating concentrations of inﬂammatory and ﬁbrosis markers
are given in Table 1. Based on HRCT ﬁndings, 66 of the 85
asbestos-exposed subjects had normal lung parenchyma
(HRTC class 0) or only minor borderline ﬁbrotic changes
(HRTC class 1) and 19 had bilateral parenchymal ﬁbrosis,
that is, asbestosis (HRCT classes 2–5) [20]. Asbestos-
exposed subjects with asbestosis were older than exposed
subjects without ﬁbrotic changes (p = 0 015, Table 1). How-
ever, there was no diﬀerence in the time since the beginning
of the exposure between these two groups (Table 1) and
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YKL-40 did not correlate with age (r = 0 102, p = 0 355,
Table 2). In subjects with asbestosis, diﬀusing capacity for
carbon monoxide (DL,CO) was decreased by 18% compared
to asbestos-exposed subjects without HRCT ﬁndings, but
there was no diﬀerence between these groups in FVC or
FEV1. Adipsin and MMP-9 levels were increased in subjects
with asbestosis (Table 1).
Plasma YKL-40 concentration (median and IQR) was
higher in subjects with asbestosis (64.4, 35.1–138.1 ng/ml)
than in asbestos-exposed subjects without asbestosis
(36.4, 27.3–76.7 ng/ml, p = 0 033) or in unexposed controls
(32.8, 23.5–59.3 ng/ml, p = 0 008), as presented in Figure 1.
In asbestos-exposed subjects, ﬁbrotic changes detected on
HRCT varied from 0 to 4, and in 32 of the 85 subjects,
no changes were observed (i.e., were classiﬁed as 0).
YKL-40 showed a positive correlation with the degree
of developing/ﬁbrotic changes (from 0.5 to 4, n = 53,
rho=0.392, p = 0 005).
To further investigate the association of YKL-40 with
asbestosis, we assessed the correlations between YKL-40
and lung function indices, inﬂammatory, and ﬁbrosis
markers (Table 2). YKL-40 was found to correlate negatively
with lung function capacity parameters FVC and FEV1
(Figure 2) and positively with inﬂammation markers CRP
and IL-6, as well as with ﬁbrosis markers adipsin and
MMP-9, adipsin showing the strongest correlation
(rho=0.459, p < 0 001, Figure 3).
4. Discussion
To our knowledge, the present study is the ﬁrst to show
increased plasma YKL-40 levels in subjects with asbestosis.
Circulating YKL-40 levels were signiﬁcantly higher in sub-
jects with asbestosis compared to subjects who did not
develop lung ﬁbrosis after moderate to heavy exposure to
asbestos or to healthy controls. Moreover, in the subjects
Table 1: Subject characteristics.
Exposed Unexposed
No ﬁbrosis Asbestosis Healthy controls
N 66 19 28
Age (years) 64.5 (6.2) 68.5 (6.0) p = 0 015 62.2 (6.6)
Time since the beginning of the exposure (years) 43.6 (0.9) 46.2 (3.4) p = 0 464
FVC (% pred) 88.8 (15.6) 83.7 (10.8) p = 0 194 99.5 (10.8)
FEV1 (% pred) 88.5 (14.2) 81.8 (12.0) p = 0 071 96.7 (11.6)
DL,CO (% pred) 106.4 (17.4) 87.1 (16.8) p < 0 001 N.A.
IL-6 (pg/ml) 3.2 (2.4–4.3) 3.2 (2.0–5.0) p = 0 728 2.1 (1.6–2.8)
CRP (μg/ml) 0.93 (0.37–1.99 1.20 (0.60–2.94) p = 0 282 0.47 (0.27–1.00)
Adipsin (ng/ml) 893 (777–1069) 1022 (950–1224) p = 0 004 908 (757–1045)
MMP-9 (ng/ml) 28.1 (22.4–36.9) 54.7 (32.8–70.9) p < 0 001 30.3 (25.4–38.9)
Values are presented as mean (SD) or median (IQR) when appropriate according to the distribution of variables. FVC: forced vital capacity; FEV1: forced
expiratory volume in 1 second; DL,CO: diﬀusing capacity for carbon monoxide; IL-6: interleukin 6; CRP: C-reactive protein; MMP-9: matrix
metalloproteinase-9; N.A: not assessed. p values were calculated between asbestos-exposed subjects without ﬁbrosis and asbestos-exposed subjects with
asbestosis using unpaired t-test or Mann–Whitney U test when appropriate.
Table 2: Correlations between YKL-40 and other parameters in
asbestos-exposed subjects (n = 85).
YKL-40
Age (years) r = 0 102 p = 0 355
FVC (% pred) r = −0 259 p = 0 018
FEV1 (% pred) r = −0 240 p = 0 028
DL,CO (% pred) r = 0 127 p = 0 246
IL-6 (pg/ml) rho = 0.314 p = 0 003
CRP (μg/ml) rho = 0.371 p < 0 001
Adipsin (ng/ml) rho = 0.459 p < 0 001
MMP-9 (ng/ml) rho = 0.243 p = 0 025
Pearson’s (r) or Spearman’s (rho) correlation coeﬃcient was used according
to the distribution of variables. FVC: forced vital capacity; FEV1: forced
expiratory volume in 1 second; DL,CO: diﬀusing capacity for carbon
monoxide; IL-6: interleukin 6; CRP: C-reactive protein; MMP-9: matrix
metalloproteinase-9.
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Figure 1: Plasma YKL-40 concentrations in subjects with asbestosis
(n = 19), asbestos-exposed subjects who did not develop lung
ﬁbrosis (n = 66), and healthy controls (n = 28). Medians and
interquartile ranges (IQR) of the three groups are shown. One-
way ANOVA with least signiﬁcant diﬀerence (LSD) posttest was
used. ns: not signiﬁcant.
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exposed to asbestos, plasma YKL-40 was negatively associ-
ated with lung function parameters (FVC and FVE1) and
positively with biomarkers of inﬂammation and tissue injury
suggesting a role for YKL-40 in the formation of pulmonary
ﬁbrosis following exposure to asbestos.
Supporting our ﬁndings, previous studies have shown
increased levels of YKL-40 in other ﬁbrotic pulmonary dis-
eases. Increased levels of YKL-40 have been shown in
patients with idiopathic pulmonary ﬁbrosis, IPF [9, 15, 21],
in which high YKL-40 levels were associated with progres-
sion of the disease [9, 21]. YKL-40 levels have been shown
to associate also with other idiopathic interstitial lung
diseases including nonspeciﬁc interstitial pneumonia,
smoking-related interstitial lung disease, and cryptogenic
organizing pneumonia [16], pulmonary sarcoidosis [22],
posttransplantation bronchiolitis obliterans [23], and pulmo-
nary manifestations of cystic ﬁbrosis or systemic sclerosis
[24–26]. Corradi et al. reported increased YKL-40 levels also
in patients with malignant mesothelioma (n = 50), a disease
often associated with asbestos exposure [27]. These studies
support our results that high levels of YKL-40 are associated
with the pathogenic process in asbestosis and other ﬁbrotic
pulmonary diseases.
The eﬀects of asbestos exposure depend on several factors
including the intensity and duration of the exposure, ﬁber
type and size, and susceptibility of the exposed individual.
Asbestosis is related especially to long (>20μm) ﬁbers, and
low-dose exposure associates with a macrophage-dominant
immune response whereas high doses of asbestos lead to
neutrophil-dominant inﬂammation. Ingestion of asbestos
activates macrophages, in a pattern typical for alternatively
activated M2 macrophages related to wound healing and
ﬁbrosis, to produce growth factors and cytokines that pro-
mote collagen formation in the ﬁbroblasts [1, 28]. Intrigu-
ingly, YKL-40 is produced by human monocyte-derived
diﬀerentiated macrophages [10] and has been suggested as
a marker of alternatively activated M2 macrophages [28].
In peripheral blood of IPF patients, high levels of circulating
YKL-40 were accompanied with M2-skewed gene expression
proﬁle in the peripheral blood mononuclear cells (PBMCs)
[9]. Moreover, YKL-40 was a direct stimulator of alternative
activation in mice alveolar and peritoneal macrophages [29].
In asbestos-exposed rats, alveolar macrophages were shown
to have altered phenotype with long survival and high growth
factor production resulting in ﬁbrogenesis [30]. These ﬁnd-
ings suggest YKL-40 as a marker of M2 macrophage-driven
ﬁbrogenic processes in asbestosis, which could be potentially
preventable by aﬀecting YKL-40 levels.
In addition to its role in alternative activation of mac-
rophages, there are several other possible eﬀector functions
for YKL-40 in asbestosis. Asbestos is known to induce for-
mation of reactive oxygen species (ROS) in macrophages,
on the surface of asbestos ﬁbers and in the mitochondria
of several cell types contributing to DNA damage and sub-
sequent pulmonary toxicity through oxidative stress [1].
YKL-40, in turn, has been suggested to protect the lung
by inhibiting oxidant-induced injury, vascular permeabil-
ity, and apoptosis [8]. Moreover, YKL-40 is able to bind
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Figure 2: Correlations between YKL-40 and measures of respiratory function in asbestos-exposed subjects (n = 85). YKL-40 correlated with
(a) FVC: forced vital capacity and (b) FEV1: forced expiratory volume in 1 second. Pearson’s correlation coeﬃcient was used because of
skewed distribution of the data.
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Figure 3: Correlation between YKL-40 and ﬁbrosis marker adipsin
in asbestos-exposed subjects (n = 85). YKL-40 correlated positively
with adipsin. Spearman’s correlation coeﬃcient was used because
of skewed distribution of the data.
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collagen types I, II, and III and to have modulatory eﬀects
on collagen ﬁbrillation and collagenolytic cleavage, which
could play a part in the ﬁbrotic process [31].
In the present study, to assess the role of YKL-40 in
asbestosis, we examined its associations with markers known
to relate to the disease. YKL-40 showed positive correlations
to markers of inﬂammation and ﬁbrosis, supporting the view
that YKL-40 is linked to the pathogenesis of asbestosis. First,
plasma YKL-40 correlated with inﬂammation markers CRP
and IL-6 in asbestos-exposed subjects. This is supported by
previous studies showing similar ﬁndings in patients with
heart transplantation, atrial ﬁbrillation, type 2 diabetes, or
rheumatoid arthritis [32–35] and in subjects during ongoing
dialysis treatment [36]. Moreover, IL-6 has previously been
shown to stimulate YKL-40 secretion from human
chondrocytes [37] and human bone marrow-derived stem
cells [38]. Circulating levels of IL-6 have been shown to
be increased in asbestos-exposed subjects [39, 40] and
suggested to be secreted from type II alveolar cells [39].
However, macrophages have been implicated also as a
possible source for IL-6 [10, 41].
Secondly, YKL-40 correlated with adipsin and MMP-9,
markers that were also found to be increased in subjects with
asbestosis in the present study. Plasma adipsin has been
shown to be associated with the degree of lung ﬁbrosis in
asbestos-exposed subjects [20]. The association of YKL-40
and adipsin has not been reported before. Our ﬁnding on
the association of YKL-40 with MMP-9 is supported by ﬁnd-
ings in previous in vitro studies. YKL-40 has been shown to
stimulate MMP-9 synthesis in BAL alveolar macrophages
from smoking COPD patients [42] and in human ﬁbroblasts
from nasal mucosa [43]. Moreover, in cultured murine mac-
rophages, YKL-40 has been reported to stimulate MMP-9
expression and inhibition of YKL-40 with siRNA was found
to decrease MMP-9 expression [44].
In the present study, subjects with asbestosis had on aver-
age a mild disease with well-preserved lung function and had
not yet developed severe restrictive lung function which can
be regarded as a limitation of the study. OnlyDL,COwas signif-
icantly lower in asbestosis subjects.However, at present, this is
characteristic to asbestosis diagnosed in industrialized coun-
tries: most cases of asbestosis are detected in an early phase
when they show up only on radiological examinations prior
to possible progression to severe restriction or respiratory
insuﬃciency [45]. The asbestos-exposed groupwithout asbes-
tosismaywell developasbestosis in the comingyears, although
time after the beginning of the exposure was similar in both
groups. Ourﬁnding on the increasedYKL-40 levels in subjects
with asbestosis compared to subjects who had not developed
lung ﬁbrosis may thus well reﬂect the early ﬁbrotic changes
detected byHRCT. Furthermore, we present here correlations
of YKL-40 with known inﬂammatory and ﬁbrotic markers,
which may reﬂect interesting possible mechanisms in the
pathogenesis of asbestosis. Additional experimental studies
are needed to conﬁrm if the observed correlations are trans-
lated to causality. However, previous results in the scientiﬁc
literature do suggest that YKL-40 could also play a role in the
pathogenesis of ﬁbrotic changes and the ﬁndings presented
in our clinical cohort support these intriguing hypotheses.
Improved biomarkers and treatment options are needed
in the diagnostics andmanagement of ﬁbrotic pulmonary dis-
eases. According to our ﬁndings, YKL-40 could be a potential
novel biomarker for ﬁbrosis and inﬂammation in asbestosis.
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